Study title: "Behandlung einer Hemmkörperhämophilie B mit hochdosierter Factor IX-Substitution. In: Landbeck,G., Marx R. (Hrsg.): 15 Hämophilie-Symposium Hamburg, 1984, Springer-Verlag, Berlin, Heidelberg, New York, Tokyo: 251-254 (1986).(Kraus B et al.) " "Behandlung einer Hemmkörperhämophilie B mit hochdosierter Factor IX-Substitution. In: Landbeck,G., Marx R. (Hrsg.): 15 Hämophilie-Symposium Hamburg, 1984, Springer-Verlag, Berlin, Heidelberg, New York, Tokyo: 251-254 (1986).(Kraus B et al.) "
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Hemic and Lymphatic Diseases | |||||
| Brands: Please see report, Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: PROTHROMBIN | |||||
| ATC code: B02BD03 | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | - | |